

REMARKS

Claims 1-13 are currently pending in the application. Applicant cancels claim 5 without prejudice. Claims 1, 3, 8, 10, and 12 are in independent form.

Claims 1-13 stand rejected under 35 U.S.C. §112, first paragraph, as failing to comply with the written description requirement. Specifically, the Office Action holds that isolation and culture of mesenchymal stem cells is disclosed as well as how phosphodiesterase inhibitors can be used to promote neurogenesis in rats, but not a patient in need of neurogenesis. The Office Action holds that there is no mention of how mesenchymal stem cells can be used to promote neurogenesis to a patient in need of neurogenesis promotion, and there are also no working examples of stem cells combined with a phosphodiesterase inhibitor promoting neurogenesis of increasing neurological function.

In response thereto, Applicant and others have demonstrated that ischemic stroke induces neurogenesis in the adult rat and mouse (see references listed herein - Zhang, et al. (2001); Jin, et al. (2001); Parent, et al. (2002); Arvidsson, et al. (2002); Zhang, et al. (2004)). Stroke-induced neurogenesis has also recently been demonstrated in the adult human brain, even in advanced age patients (Macas, et al. (2006); Curtis, et al. (2007)). Transplantation of rodent or human mesenchymal stromal cells (MSCs) substantially enhances neurogenesis and improves neurological functions after stroke in the rat (Chopp, et al. (2002); Chen, et al. (2003)). Based on these data, Applicant predicted that administration of MSCs promotes endogenous neurogenesis in stroke patients. Although there are no data showing that MSCs enhance neurogenesis in human patients, clinical trials in humans with stroke and spinal cord injury show that intravenous administration of bone marrow cells or direct transplantation of autologous whole bone marrow into

the site of spinal cord injury improves neurological function significantly improves neurological function after stroke and spinal cord injury, respectively. (Park, et al. (2005); Bang, et al. (2005)).

Rat models of disease are widely employed for the development of many treatments. It is thus accepted methodology for one skilled in the art of neurogenesis to use the rat model of Applicant and apply results of the rat model to humans. Modern medical science emerges from the laboratory and from animal models of disease. Reconsideration of the rejection is respectfully requested.

Claims 1, 3, 5-8, 10, and 12 stand rejected under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 6,075,028 to Graham. Specifically, the Office Action holds that Graham discloses a method of using a phosphodiesterase, sildenafil, to treat Tourette's syndrome and other related central nervous system (CNS) disorders. Promotion of neurogenesis and increasing neurological function would inevitably be involved by this treatment, since someone having Tourette's would be in need of neurogenesis promotion. Reconsideration of the rejection under 35 U.S.C. § 102(b), as anticipated by Graham, as applied to the claims is respectfully requested. Anticipation has always been held to require absolute identity in structure between the claimed structure and a structure disclosed in a single reference.

Graham discloses that sildenafil transiently reduces neurological symptoms of Tourette's syndrome because the symptoms return when administration of sildenafil is ceased. Graham does not provide any mechanisms underlying the effect of sildenafil on reduction of the symptoms. Nowhere in Graham is there any statement or inference to neurogenesis in the brain and brain plasticity. Applicant's data demonstrate that sildenafil enhanced-neurogenesis and functional outcome persist

for at least 20 days after termination of the use of the drug (Zhang, et al. (2002)). Doses of sildenafil used in Applicant's studies are 2, 5, and 10 mg/kg, which are higher than doses used in Graham. In addition, Applicant demonstrates that agents which increase cGMP levels such as sildenafil act directly on neural progenitor cells in brain to induce the production of new neural cells (Zhang, et al. (2002); Wang, et al. (2005); Chen, et al. (2003); Chen, et al. (2005); Chen, et al. (2006); Lu, et al. (2007); Zhang, et al. (2005); Zhang, et al. (2006)). Tourette's syndrome is not a form of neural injury where cerebral tissue is infarcted. In Tourette's, there are no neurological deficits, only abnormal behavior, in sharp contrast to stroke. Treatment of stroke with sildenafil evokes neurogenesis and brain remodeling, mechanisms of action which cannot be inferred by the transient amelioration of behavioral symptoms present in Tourette's patients.

Applicant has further amended the independent claims to positively set forth method steps requiring promoting neurogenesis, augmenting production of neurons, and increasing neurological and cognitive function in the patient to which the phosphodiesterase inhibitor is administered. Further, independent claim 3 requires an effective amount of a phosphodiesterase inhibitor sufficient to promote neurogenesis. Graham does not disclose any of the required method steps and certainly does not disclose an amount of sildenafil that can promote neurogenesis.

Therefore, since the Graham patent does not disclose promoting neurogenesis with a phosphodiesterase inhibitor as set forth in the presently pending independent claims, the claims are patentable over the Graham patent and reconsideration of the rejection is respectfully requested.

Claims 3 and 4 stand rejected under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 5,827,740 to Pittenger. Specifically, the Office Action holds that

Pittenger claims a composition of stem cells and a phosphodiesterase inhibitor. Reconsideration of the rejection under 35 U.S.C. § 102(b), as anticipated by Pittenger, as applied to the claims is respectfully requested. Anticipation has always been held to require absolute identity in structure between the claimed structure and a structure disclosed in a single reference.

Pittenger discloses a method of directing MSCs to differentiate into adipocytes by treating them with glucocorticoid and a compound that elevates cAMP, i.e. a phosphodiesterase inhibitor. Adipose tissue is used as energy storage and releases fatty acids when a person does not take in enough calories. Pittenger does not disclose anything about neurogenesis. The phosphodiesterase inhibitor of Pittenger is merely used to differentiate the MSCs, not for actual treatment of the patient. Thus, Pittenger does not disclose an effective amount of a phosphodiesterase inhibitor to promote neurogenesis. The effective amount for promoting neurogenesis is different from that required to be an effective amount for inducing adipogenic differentiation.

Therefore, since the Pittenger patent does not disclose a compound for promoting neurogenesis comprising an effective amount of a phosphodiesterase inhibitor sufficient to promote neurogenesis as set forth in the presently pending independent claim, the claim is patentable over the Pittenger patent and reconsideration of the rejection is respectfully requested.

Claims 1-13 stand rejected under 35 U.S.C. §103(a) as being unpatentable over Graham in view of International Patent Application Publication No. WO/2000/050568 to Price. Specifically, the Office Action holds that Graham teaches treating Tourette's syndrome by administering sildenafil. Since someone having Tourette's syndrome would be in need of neurogenesis promotion, the Office Action holds that it meets this

limitation. The Office Action holds that neurotransmission dysfunction is implicated with Tourette's, and Alzheimer's is also associated with neurotransmission dysfunction. The Office Action also holds that Price discloses a method of promoting neurogenesis or increasing neurological function (since they treat Alzheimer's) that includes cellular therapy. Therefore, the Office Action holds that it would have been obvious for one skilled in the art to use the cellular therapy of Price with the sildenafil of Graham. Reconsideration of the rejection under 35 U.S.C. §103(a), as being unpatentable over Graham in view of Price is respectfully requested.

"Any need or problem known in the field of endeavor at the time of invention and addressed by the patent can provide a reason for combining the elements in the manner claimed"; however, that reason must be present for the combination to be obvious. *KSR Intern Co. v. Teleflex*, 127 S. Ct. 1727, 1742, U.S. (2007). This requirement was confirmed in *Takeda Chem. Indust., et al. v. Alphapharm*, No. 06-1329 (Fed. Cir. 2007).

There is no reason why one skilled in the art would combine Graham and Price. Graham is concerned with Tourette's syndrome and symptoms, regardless of whether other diseases are mentioned. As stated above, in Tourette's, there are no neurological deficits, only abnormal behavior, in sharp contrast to stroke dealt with in the present invention. Treatment of stroke with sildenafil evokes neurogenesis and brain remodeling, mechanisms of action which cannot be inferred by the transient amelioration of behavioral symptoms present in Tourette's patients. Thus, if anything, Graham is comparing the symptoms of Tourette's to some similar symptoms of Alzheimer's. A Tourette's patient is not in need of neurogenesis, thus one would not use the stem cells of Price to treat damaged brain. In contradistinction, the presently pending claims relate to promoting neurogenesis and provide new neural growth, along with tissue growth from cellular therapy.

Therefore, it would not be obvious to combine Graham and Price to arrive at the present invention as claimed in the presently pending independent claims.

Since neither the cited references alone or in combination with knowledge in the art suggest the currently claimed invention, it is consequently respectfully submitted that the claims are clearly patentable over the combination, even if the combination were to be applied in opposition to applicable law, and reconsideration of the rejection is respectfully requested.

The remaining dependent claims not specifically discussed herein are ultimately dependent upon the independent claims. References as applied against these dependent claims do not make up for the deficiencies of those references as discussed above, and the prior art references do not disclose the characterizing features of the independent claims discussed above. Hence, it is respectfully submitted that all of the pending claims are patentable over the prior art.

In view of the present amendment and foregoing remarks, reconsideration of the rejections and advancement of the case to issue are respectfully requested.

References cited:

1. Zhang RL, Zhang ZG, Zhang L, Chopp M. Proliferation and differentiation of progenitor cells in the cortex and the subventricular zone in the adult rat after focal cerebral ischemia. *Neuroscience*. 2001;105:33-41
2. Jin K, Minami M, Lan JQ, Mao XO, Batteur S, Simon RP, Greenberg DA. Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat. *Proc Natl Acad Sci U S A*. 2001;98:4710-4715.

3. Parent JM, Vexler ZS, Gong C, Derugin N, Ferriero DM. Rat forebrain neurogenesis and striatal neuron replacement after focal stroke. *Ann Neurol.* 2002;52:802-813.
4. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. *Nat Med.* 2002;8:963-970.
5. Zhang R, Zhang Z, Wang L, Wang Y, Goussev A, Zhang L, Ho KL, Morshead C, Chopp M. Activated neural stem cells contribute to stroke-induced neurogenesis and neuroblast migration toward the infarct boundary in adult rats. *J Cereb Blood Flow Metab.* 2004;24:441-448
6. Macas J, Nern C, Plate KH, Momma S. Increased generation of neuronal progenitors after ischemic injury in the aged adult human forebrain. *J Neurosci.* 2006;26:13114-13119
7. Curtis MA, Eriksson PS, Faull RL. Progenitor cells and adult neurogenesis in neurodegenerative diseases and injuries of the basal ganglia. *Clin Exp Pharmacol Physiol.* 2007;34:528-532
8. Chopp M, Li Y. Treatment of neural injury with marrow stromal cells. *Lancet Neurol.* 2002;1:92-100
9. Chen J, Li Y, Katakowski M, Chen X, Wang L, Lu D, Lu M, Gautam SC, Chopp M. Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. *J Neurosci Res.* 2003;73:778-786
10. Park HC, Shim YS, Ha Y, Yoon SH, Park SR, Choi BH, Park HS. Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor. *Tissue Eng.* 2005;11:913-922


11. Bang et al, Autologous mesenchymal stem cell transplantation in stroke patients. *Annals of Neurology*. 2005;57:874-882.
12. Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M, Chopp M. Sildenafil (viagra) induces neurogenesis and promotes functional recovery after stroke in rats. *Stroke*. 2002;33:2675-2680.
13. Wang L, Gang Zhang Z, Lan Zhang R, Chopp M. Activation of the pi3-k/akt pathway mediates cgmmp enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. *J Cereb Blood Flow Metab*. 2005;25:1150-1158
14. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, Zhang C, Lu M, Katakowski M, Feldkamp CS, Chopp M. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. *Ann Neurol*. 2003;53:743-751
15. Chen J, Zhang C, Jiang H, Li Y, Zhang L, Robin A, Katakowski M, Lu M, Chopp M. Atorvastatin induction of vegf and bdnf promotes brain plasticity after stroke in mice. *J Cereb Blood Flow Metab*. 2005;25:281-290
16. Chen J, Zacharek A, Li A, Zhang C, Ding J, Roberts C, Lu M, Kapke A, Chopp M. Vascular endothelial growth factor mediates atorvastatin-induced mammalian achaete-scute homologue-1 gene expression and neuronal differentiation after stroke in retired breeder rats. *Neuroscience*. 2006;141:737-744
17. Lu D, Qu C, Goussev A, Jiang H, Lu C, Schallert T, Mahmood A, Chen J, Li Y, Chopp M. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal ca3 region, and improve spatial learning in rat after traumatic brain injury. *J Neurotrauma*. 2007;24:1132-1146
18. Zhang L, Zhang RL, Wang Y, Zhang C, Zhang ZG, Meng H, Chopp M. Functional recovery in aged and young rats after embolic stroke: Treatment with a phosphodiesterase type 5 inhibitor. *Stroke*. 2005;36:847-852

19. Zhang RL, Zhang Z, Zhang L, Wang Y, Zhang C, Chopp M. Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia. *J Neurosci Res.* 2006;83:1213-1219

The Commissioner is authorized to charge any fee or credit any overpayment in connection with this communication to our Deposit Account No. 11-1449.

Respectfully submitted,

KOHN & ASSOCIATES, PLLC



Kenneth I. Kohn, Reg. No. 30,955
Customer No.: 48924

Dated: November 29, 2007

CERTIFICATE OF ELECTRONIC FILING VIA EFS-WEB

Date of Electronic Filing: 11-29-07

I hereby certify that this correspondence is being electronically filed with the United States Patent & trademark Office on the above date.


Connie Herty